RCT: Overall survival benefit with Tebentafusp in metastatic uveal melanoma.
28 Sep, 2021 | 09:03h | UTC
Commentary on Twitter
Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. https://t.co/HnSdWItKIp pic.twitter.com/qu4huRn3Mu
— NEJM (@NEJM) September 27, 2021